USPTO Examiner MI QIUWEN - Art Unit 1655

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19417541ACACIA NILOTICA BASED HYDROGEL AND METHOD OF MAKING THE SAMEDecember 2025February 2026Allow200NoNo
19205709Vaporized Medicants and Methods of UseMay 2025January 2026Abandon810NoNo
19190359ANTIMICROBIAL COMPOSITIONS AND METHODS FOR MAKING AND USING THE SAMEApril 2025November 2025Allow710YesNo
19187591STORAGE STABLE FORMULATIONS OF SULFATED GLYCOSAMINOGLYCANS AND FRAGMENTS DERIVED THEREFROM FOR THE TREATMENT OF PAIN AND OTHER MEDICAL CONDITIONSApril 2025January 2026Allow911NoNo
19187241STORAGE STABLE FORMULATIONS OF SULFATED GLYCOSAMINOGLYCANS AND FRAGMENTS DERIVED THEREFROM FOR THE TREATMENT OF PAIN AND OTHER MEDICAL CONDITIONSApril 2025January 2026Allow920NoNo
19066076METHOD FOR PRODUCING A PLANT-BASED EXTRACT COMPOSITION HAVING THE EFFECT OF ENHANCING NUTRITION AND IMMUNITYFebruary 2025June 2025Allow411YesNo
19012840POLYSACCHARIDE COMPOUND WITH A DEFINED MOLECULAR STRUCTURE THAT CAN ELIMINATE THE TOXIC SIDE EFFECTS OF CHEMOTHERAPY DRUGSJanuary 2025June 2025Allow501YesNo
18980483TRADITIONAL CHINESE MEDICINE COMPOSITION FOR TREATING CORONARY MYOCARDIAL BRIDGE AND APPLICATION THEREOFDecember 2024July 2025Allow711YesNo
18961323RHODOSORUS MARINUS AND APPLICATION THEREOF IN PREPARING FACIAL MASKSNovember 2024June 2025Allow711NoNo
18948016PEONY STAMEN-DODDER COMPOSITE, AND ITS PREPARATION METHOD AND APPLICATIONNovember 2024January 2025Allow200YesNo
18926515GAME ATTRACTANT AND VARMINT REPELLENT COMPOSITIONS AND METHODSOctober 2024March 2025Allow511YesNo
18911447MEDICINAL MUSHROOM-BASED TOPICAL COMPOSITIONOctober 2024January 2025Allow411YesNo
18906311MEDICAL TREATMENT COMPOSITION, METHOD OF PREPARATION AND TREATMENT METHODOctober 2024May 2025Allow710YesNo
18844892METHOD FOR IMPROVING HEALTH CONDITION OF MAMMAL OR FARM ANIMALSeptember 2024February 2025Allow500NoNo
18806195SKIN CARE FORMULATIONSAugust 2024October 2025Allow1400NoNo
18794793ANTIMICROBIAL COMPOSITIONS AND METHODS FOR MAKING AND USING THE SAMEAugust 2024January 2025Allow501YesNo
18764014FORMULATIONS AND METHODS FOR SKIN CAREJuly 2024December 2024Allow511YesNo
18760356COSMETIC COMPOSITIONJuly 2024February 2026Allow2010YesNo
18757390STORAGE STABLE FORMULATIONS OF SULFATED GLYCOSAMINOGLYCANS AND FRAGMENTS DERIVED THEREFROM FOR THE TREATMENT OF PAIN AND OTHER MEDICAL CONDITIONSJune 2024December 2024Allow510NoNo
18750691STORAGE STABLE FORMULATIONS OF SULFATED GLYCOSAMINOGLYCANS AND FRAGMENTS DERIVED THEREFROM FOR THE TREATMENT OF PAIN AND OTHER MEDICAL CONDITIONSJune 2024March 2025Allow921NoNo
18736592TRADITIONAL CHINESE MEDICINE COMPOUND FOR PREVENTING AND TREATING AFRICAN SWINE FEVER, AND ITS EFFICIENCY ENHANCEMENT PROCESS AND APPLICATIONJune 2024October 2024Allow501NoNo
18736009PEST CONTROL USING NATURAL PEST CONTROL AGENT BLENDSJune 2024January 2025Allow821YesNo
18734602PHARMACEUTICAL COMPOSITION AND COSMETIC COMPOSITIONJune 2024April 2025Allow1001YesNo
18734385PHOSPHOLIPID COMPOSITIONS FOR DELIVERY OF THERAPEUTIC COMPOUNDSJune 2024December 2025Allow1810NoNo
18669211Composition for Relieving Sleep Disorder and its Application Method ThereofMay 2024December 2024Allow700YesNo
18667139HERBAL COMPOSITION PHY906 AND ITS USE IN CHEMOTHERAPYMay 2024January 2025Allow800YesNo
18709625SKIN CARE COMPOSITIONMay 2024March 2026Allow2200YesNo
18661900COMPOSITION FOR TREATING BONE LOSSMay 2024July 2024Allow200NoNo
18659701COMPOSITIONS OF HERBAL FORMULATIONS AND USES THEREOFMay 2024May 2025Allow1301YesNo
18655974STABILIZED COMPOSITIONS COMPRISING CANNABIDIOLMay 2024January 2025Allow901YesNo
18654377BARRIER GUARD TECHNOLOGYMay 2024December 2024Allow800YesNo
18639285METHODS OF TREATING ENDOMETRIOSIS AND OTHER NONCANCER GYNECOLOGICAL DISORDERS WITH HEMP EXTRACTApril 2024May 2025Allow1311YesNo
18635597METHODS OF TREATING OVARIAN CANCER WITH HEMP EXTRACTApril 2024June 2025Allow1410NoNo
18621062TRADITIONAL CHINESE MEDICINE COMPOUND FOR IMPROVING TESTICULAR DYSFUNCTION, PREPARATION METHOD AND APPLICATION THEREOFMarch 2024October 2024Allow711YesNo
18436468FOODS TO PROMOTE BETTER HEALTH AND/OR TO MAINTAIN HOMEOSTAIS AND METHOD OF PRODUCTION THEREOFFebruary 2024December 2024Allow1011YesNo
18432512TIME RELEASE SLEEP AID SYSTEMFebruary 2024May 2025Allow1611YesNo
18294676COMPOSITION BASED ON CROCUS SATIVUS AND CANNABIS SATIVAFebruary 2024December 2025Allow2300NoNo
18431386TOPICAL COMPOSITIONSFebruary 2024August 2025Abandon1921NoNo
18429310SUSTAINABLE NANOCOMPOSITION FOR TREATMENT OF OSTEOPOROSISJanuary 2024June 2024Allow501NoNo
18426754BIOFABRICATION OF VAGINAL SUPPORT USING VAGINALLY DERIVED CELLSJanuary 2024December 2025Allow2300YesNo
18415902HOMEOPATHIC THERAPEUTIC METHOD AND COMPOSITIONSJanuary 2024November 2025Abandon2211NoNo
18410512PHYTOCHEMICAL/ NUTRACEUTICAL COMPOSITION FOR MULTIMODAL PROPHYLAXIS AGAINST AND TREATMENT OF VIRAL AND BACTERIAL INFECTION AND INFLAMMATIONJanuary 2024May 2025Allow1621YesNo
18409486METHOD AND COMPOSITION FOR REVERSING AND/OR INHIBITING ATHEROSCLEROSISJanuary 2024February 2026Allow2510NoNo
18407411METHOD OF PREVENTING CADMIUM-INDUCED LIVER TOXICITY USING A PLANT PRODUCT DERIVED FROM ACHILLEA MILLEFOLIUM L.January 2024August 2024Allow710NoNo
18576255USE OF A VEGETAL EXTRACT FROM SALVIA HAENKEI AS AN ACTIVE AGENT IN THE TREATMENT OF A MUSCULOSKELETAL DISORDERJanuary 2024February 2026Allow2510NoNo
18574200COMPOSITIONS FOR THE TREATMENT OF HYPOPIGMENTATIONDecember 2023December 2025Allow2400NoNo
18391194METHOD OF TREATING ILLNESS USING LYOPHILIZED CAMEL URINEDecember 2023September 2024Allow911YesNo
18538812BOTANICAL FORMULATIONSDecember 2023December 2024Allow1201YesNo
18533558AQUEOUS WOUND HEALING FORMULATIONDecember 2023June 2025Abandon1811YesNo
18531785CURCUMIN-BASED COMPOSITIONS & METHODS OF USE THEREOFDecember 2023September 2025Abandon2110NoNo
18529504COMPOSITION FOR TREATING BONE LOSSDecember 2023April 2024Allow511YesNo
18519895GYNOSTEMMA PENTAPHYLLUM TEA OR GYNOSTEMMA PENTAPHYLLUM TEA EXTRACT CONTAINING GYPENOSIDE L AND GYPENOSIDE LI AND ANTIOBESITY USE THEREOFNovember 2023February 2026Allow2710YesNo
18519477COSMETIC COMPOSITIONSNovember 2023August 2025Abandon2121NoNo
18518089TRADITIONAL CHINESE MEDICINE COMPOSITION FOR PREVENTING AND TREATING DIABETES, TRADITIONAL CHINESE MEDICINE PREPARATION, AND USE THEREOFNovember 2023October 2025Allow2300YesNo
18515789CRYSTALLINE FORMS OF PSILACETINNovember 2023August 2024Allow901YesNo
18514659METHOD FOR PREPARING STABLE LIQUID EMULSION FORMS OF PLANT EXTRACTNovember 2023December 2025Allow2520NoNo
18512157PEST CONTROL USING NATURAL PEST CONTROL AGENT BLENDSNovember 2023March 2024Allow410YesNo
18509499COMPOSITION FOR PREVENTING OR TREATING GASTRITIS OR PEPTIC ULCERNovember 2023March 2025Allow1610NoNo
18388854THERAPEUTIC TREATMENT FOR THE CORONAVIRUS DISEASE COVID-19November 2023September 2025Allow2210YesNo
18388823THERAPEUTIC TREATMENT FOR THE CORONAVIRUS DISEASE COVID-19November 2023September 2025Allow2210YesNo
18505309Topical NSAID Formulation with Improved Skin AbsorptionNovember 2023February 2025Abandon1511NoNo
18559889USE OF EXTRACELLULAR VESICLES OF RHIZOMA DRYNARIAE IN PREPARATION OF MEDICINE FOR TREATING ORTHOPEDIC DISEASESNovember 2023April 2025Allow1710NoNo
18388167METHOD OF TREATMENT OF CANCERSNovember 2023April 2024Allow610YesNo
18387298MEDICAL TREATMENT COMPOSITION, METHOD OF PREPARATION AND TREATMENT METHODNovember 2023June 2024Allow801YesNo
18384037SKIN PENETRATION ENHANCER FOR ROYAL JELLYOctober 2023December 2025Allow2610NoNo
18493997STABILIZED COMPOSITIONS COMPRISING CANNABIDIOLOctober 2023April 2024Allow611YesNo
18381558BETA-ADRENERGIC AGONIST AND MUSCARINIC ANTAGONIST COMPOSITIONS AND METHODS OF USINGOctober 2023April 2024Allow611YesNo
18381439PHOSPHOLIPID COMPOSITIONS FOR DELIVERY OF THERAPEUTIC COMPOUNDSOctober 2023April 2024Allow601YesNo
18487399UVARIA GRANDIFLORA EXTRACT AS A BOTANICAL FUNGICIDE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOFOctober 2023October 2024Abandon1211NoNo
18379955COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING TISSUE INJURY AND DISEASEOctober 2023March 2025Allow1710NoNo
18476580STORAGE STABLE FORMULATIONS OF SULFATED GLYCOSAMINOGLYCANS AND FRAGMENTS DERIVED THEREFROM FOR THE TREATMENT OF PAIN AND OTHER MEDICAL CONDITIONSSeptember 2023April 2024Allow711YesNo
18367577Preparation Method of Ginseng Composition with High Ginsenoside BioavailabilitySeptember 2023January 2024Allow411YesNo
18464967Composition for Relieving Sleep Disorder and its Application Method ThereofSeptember 2023April 2024Allow711YesNo
18463921COSMETIC COMPOSITION CONTAINING EXTRACT OF CYPERUS ROTUNDUS FOR ANTI-INFLAMMATION, SKIN SOOTHING, IRRITATION RELIEF, AND SKIN BARRIER ENHANCEMENTSeptember 2023December 2025Allow2710YesNo
18241567CURCUMIN COMPOSITIONS AND METHODS OF USE AS AN NK3 ANTAGONISTSeptember 2023April 2024Allow800YesNo
18239560OIL-BASED INSECTICIDAL AND INSECT REPELLENT COMPOSITIONSAugust 2023November 2024Allow1510YesNo
18547601PERSONALIZED SKIN CARE COMPOSITIONSAugust 2023August 2025Allow2400NoNo
18547384COSMETIC COMPOSITION COMPRISING BLACK YEAST-DERIVED EXOSOMESAugust 2023October 2025Allow2500NoNo
18278129COSMETIC COMPOSITION FOR DEFORMED NAIL CARE AND PREPARATION METHOD THEREOFAugust 2023October 2025Allow2600YesNo
18236081HERBAL COMPOSITION PHY906 AND ITS USE IN CHEMOTHERAPYAugust 2023May 2024Allow800YesNo
18546052NOVEL STRAIN AND USE THEREOFAugust 2023February 2026Allow3110YesNo
18364319MITOCHONDRIAL TRANSPLANTATION AND USE THEREOF IN OCULAR DISEASESAugust 2023August 2025Allow2500YesNo
18275364FERMENTED APPLE COMPOSITIONAugust 2023February 2026Allow3010YesNo
18228222COMPOSITION FOR A FECAL-DERIVED STERILIZED POSTBIOTIC IN ANTI-AGING AND NEUROTHERAPEUTIC APPLICATIONSJuly 2023June 2024Allow1121YesNo
18226387PROMOTING GROWTH, YIELD, AND SALINITY TOLERANCE OF ACHILLEA FRAGRANTISSIMAJuly 2023November 2023Allow411NoNo
18262924COMBINATION OF SCUTELLARIA EXTRACTS WITH CITRUS BERGAMIA OR CYNARA CARDUNCULUS EXTRACTS AND FORMULATIONS CONTAINING THEMJuly 2023February 2026Abandon3110NoNo
18357668USE OF ANTRODIA CINNAMOMEA FOR INCREASING ALCOHOL METABOLISM OR/AND HANGOVERJuly 2023August 2024Allow1310NoNo
18353992HORSERADISH AND CINNAMON MIXED EXTRACT COMPOSITION FOR SUPPRESSION OF AVIAN VIRAL EPIDEMIC DISEASESJuly 2023December 2023Allow510YesNo
18353169SAPONIN EXTRACTIONJuly 2023October 2024Abandon1510NoNo
18353172SAPONIN EXTRACTIONJuly 2023July 2024Allow1210YesNo
18222187ECM HYDROGEL FOR TREATING ESOPHAGEAL INFLAMMATIONJuly 2023January 2025Allow1810YesNo
18261332A NUTRACEUTICALS FORMULATION WITH AN ENHANCED ORGANOLEPTIC PROPERTIES USED FOR SKIN CAREJuly 2023January 2026Allow3001NoNo
18221060COMPOSITIONS AND METHODS FOR PARENTERAL ADMINISTRATION OF THERAPEUTIC AGENTSJuly 2023August 2025Abandon2521NoNo
18347535BLOOD PLASMA-CONTAINING COMPOSITIONSJuly 2023June 2025Abandon2310NoNo
18216965PROCESSES FOR PRODUCING LOW CHLOROPHYLL, HIGH POLAR LIPID COMPOSITIONS FROM ALGAL OILS AND EXTRACTSJune 2023June 2025Allow2311YesNo
18343765FREEZE-DRIED NIPA PALM POWDER AND METHOD OF MANUFACTURING THE SAMEJune 2023September 2023Allow311YesNo
18038046COMPOSITION FOR BLOCKING ULTRAVIOLET RAYS AND FINE DUST, AND PREPARATION METHOD THEREOFJune 2023December 2025Allow3101YesNo
18214706CANNABINOID COMPOSITIONS FOR VIRTUAL AND AUGMENTED REALITY EXPERIENCESJune 2023August 2025Allow2511YesNo
18214062IMMUNITY GENERATIONJune 2023November 2025Allow2910NoNo
18269362COSMETIC COMPOSITION COMPRISING FERMENTED GRAPE EXTRACTJune 2023January 2026Allow3111YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner MI, QIUWEN.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
13
Examiner Affirmed
9
(69.2%)
Examiner Reversed
4
(30.8%)
Reversal Percentile
47.2%
Lower than average

What This Means

With a 30.8% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
109
Allowed After Appeal Filing
33
(30.3%)
Not Allowed After Appeal Filing
76
(69.7%)
Filing Benefit Percentile
45.9%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 30.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner MI, QIUWEN - Prosecution Strategy Guide

Executive Summary

Examiner MI, QIUWEN works in Art Unit 1655 and has examined 1,810 patent applications in our dataset. With an allowance rate of 66.3%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 25 months.

Allowance Patterns

Examiner MI, QIUWEN's allowance rate of 66.3% places them in the 27% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.

Office Action Patterns

On average, applications examined by MI, QIUWEN receive 1.69 office actions before reaching final disposition. This places the examiner in the 35% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by MI, QIUWEN is 25 months. This places the examiner in the 78% percentile for prosecution speed. Applications move through prosecution relatively quickly with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +52.5% benefit to allowance rate for applications examined by MI, QIUWEN. This interview benefit is in the 94% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 26.7% of applications are subsequently allowed. This success rate is in the 45% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 29.1% of cases where such amendments are filed. This entry rate is in the 42% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 52.6% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 46% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 82.7% of appeals filed. This is in the 76% percentile among all examiners. Of these withdrawals, 53.2% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 55.0% are granted (fully or in part). This grant rate is in the 57% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 5.4% of allowed cases (in the 87% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.